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Session 1 & 2 Review
ART Regimen: Building Blocks
3 meds
◦ 2 fully active













Nucleoside Reverse Transcriptase Inhibitor
NRTI
Tenofovir [TDF]
◦ Need for HIV-HBV co-infxn [alternative = entecavir]
◦ Dose reduction for CrCl <50
Lamivudine [3TC]
◦ Well, tolerated
◦ in all 1st & 2nd line regimens
Abacavir [ABC]
◦ Hypersensitivity reaction = absolute contraindication
Zidovudine [AZT]
◦ Q12hr dosing
◦ NOT if hgb <8








Non-Nucleoside Reverse Transcriptase Inhibitor
NNRTI
Nevirapine [NVP]
◦ 1st line, but not for ART start
◦ SE: hypersensitivity reaction, rash, hepatitis
Efavirenz [EFV]
◦ 1st line, but not for ART start





Available Single Tablet Regimen
• AZT / 3TC / NVP
• TDF / 3TC / EFV – “B+”
• Very similar to “Atripla” 
Protease Inhibitor
PI
Lopinavir / ritonavir [LPV/r – Kaletra]
◦ 2nd line
◦ diarrhea
Atazanavir / ritonavir [ATV/r]
◦ 2nd line
◦ Do NOT use with rifampicin for MTB tx
◦ Benign hyperbili/jaundice
Darunavir / ritonavir [DRV + r]
◦ 3rd line





Not Available in Single Tablet Regimen
Integrase Strand Transfer Inhibitor
INSTI
Dolutegravir [DTG]
◦ 1st line for patients 30kg + without childbearing 
potential
◦ WHO: 1st line treatment for pregnant women
◦ SE mild: HA, insomnia, nausea
◦ Check LFTs before/after initiation if known liver disease




Available Single Tablet Regimen





























































*1st line START 



















Assumes likely resistance to at 
least 2 prior agents
◦ Assumes failure to prior treatment 
with core of:
◦ For likely NRTI resistance, “flip” the 




2 Core Agents Backbone
DTG*+
*DTG is BID if INSTI resistance






If failed on: Switch to:







































NRTI & NNRTI Switches by adverse effects
AZTABC
Hypersensitivity Reaction:


















Any suspected hypersensitivity reaction = 
STOP the ART & DO NOT re-challenge 
Give dizziness, drowsiness & 
nightmares 4 weeks to resolve
PI & INSTI Switches by adverse effects
LPV/rATV/r









32 year old female
◦ Weight loss and diarrhea for 6 months
◦ BMI now 18
◦ HIV diagnosed by rapid testing 1 month ago
How do you counsel?
What is your next step?
Case (cont)
1 months later you see her in clinic
◦ Reports full adherence
◦ Diarrhea has stopped, weight is same as on start
◦ Notes that she has been feeling depressed
What do you review?
What are your next steps?
Case (cont)
She returns for 2nd month review
◦ Nightmares developed
◦ She has stopped her ART for the past 2 weeks entirely
What is your next step?
Case (cont)
You have switched your patient to a DTG-based regimen. Her 6 month viral load returns 
detectable but < 1,000.
What is your next step?
Case (cont)
She discloses that her husband is a truck driver who travels a 3-day route each week. She has 
not disclosed to him for fear of his reaction and therefore does not take ART on days when he is 
home to avoid inadvertent disclosure.
How do you respond?
Cases
55yoM with CKD recently started on DTG/ABC/3TC develops a cough and vomiting 2 weeks after 
starting.
◦ What is going on? Do you switch ART, and if so to what?
23yoF planning pregnancy soon sees you in clinic for new HIV diagnosis & ART start.
◦ How do you counsel her on ART options?
34yoF presents with suicidal ideation after starting ART recently. She does not know her meds 
and medical records are missing.
◦ What ART might she be on, and what do you suggest?
Cases
59yoM with HTN on NVP/TDF/3TC presents with 20lb weight loss and polyuria over 3 months.
◦ What do you suspect? What studies do you order? What is your recommendation?
63yoF on NVP/AZT/3TC notes an increasingly protuberant abdomen and thinning facial soft tissue.
◦ What do you suspect? What is your recommendation?
33yoM on NVP/TDF/3TC has VL 2,350 after IAC and 3 months of good adherence.
◦ What is your recommendation?
43yoF on LPV/r/TDF/3TC with chronic diarrhea without weight loss for 3 months.
◦ What do you suspect? What is your recommendation?
